Login / Signup

COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.

Ilana Levy YurkovskiAvital LaviEran ZimranSigal GrisariuShlomzion AumannGilad ItchakiTamar BergerPia RaananiReut HarelAriel AvivNoa LaviTsila ZukermanLev ShvidelOsnat JarchowskyMartin EllisKatrin Herzog TzarfatiMaya Koren-MichowitzYehonatan SherfItai LeviOrit SoferOfer ShpilbergNagib DallyCelia SuriuAndrei BraesterSharon Ben BarouchMerav LeibaDaniela GoldsteinNadav SaridShay YeganehJabour HallounMoshe MittelmanTamar Tadmor
Published in: Leukemia & lymphoma (2021)
This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory data from haemato-oncological patients diagnosed with COVID-19 from 16 medical centers were centrally reported. Multivariate regression analyses were used to determine variables associated with severe disease, hospitalization, and mortality. In total, 313 patients were included: 103 (35.7%) developed severe/critical respiratory infection, 178 (61.4%) were hospitalized, and 60 (20.0%) died. Age > 70 years was associated with severe/critical disease (p = 0.036) and mortality (p = 0.023), hypertension with severe/critical disease (p = 0.046) and hospitalization (p = 0.001), active haemato-oncological treatment with hospitalization (p = 0.009), and remdesivir treatment was associated with decreased mortality (p = 0.021). Convalescent plasma, enoxaparin, and corticosteroids resulted in no clinical benefit. In conclusion, COVID-19 infection seems particularly severe in patients with hematological malignancies, and of all examined therapies, remdesivir appears to be the most effective.
Keyphrases